ClinicalTrials.gg
RecruitingNCT04662918Updated Oct 7, 2025

Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

An observational study in GastroIntestinal Bleeding, sponsored by Xingshun Qi. Recruiting at 23 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Xingshun Qi · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Gastrointestinal Hemorrhage with a site in China — 8 open to participants now, 9 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · China.

Started
2022
with 1 other
Observational
7 of 40
1 open now
Registered
22nd of 40
by date

Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 22nd registered.

Gastrointestinal Hemorrhage

338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.

Browse Gastrointestinal Hemorrhage studies →

Open to participants now

8 of the 40 studies in Gastrointestinal Hemorrhage with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Gastrointestinal Hemorrhage with a site in China, or all of them as a file.
02

Study summary

Acute gastrointestinal bleeding is potentially lethal in liver cirrhosis. Accurate assessment of prognosis is critical in a timely fashion. A novel model, CAGIB score, has been developed based on our Chinese multicenter retrospective study. Now, a prospective, international multicenter, observational study will be performed to further compare the performance of CAGIB versus Child-Pugh and MELD scores for evaluating the in-hospital mortality of patients with liver cirrhosis and acute gastrointestinal bleeding.

03

Conditions studied

  • GastroIntestinal Bleeding
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with liver cirrhosis and acute gastrointestinal bleeding

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with liver cirrhosis;
  2. Patients with acute gastrointestinal bleeding presenting with hematemesis, melena, and/or hematochezia;
  3. Adults (age≥18 years old).

Exclusion criteria

Exclusion Criteria:

  1. Components of , MELD, and CAGIB scores are not available;
  2. In-hospital outcomes are not evaluable.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Mortality

    Death caused by any events during hospitalizations.

    Time frame: An average of 1-6 weeks, from admission to discharge

Secondary outcomes

  1. Failure to control bleeding within 5 days

    Failure is defined as death or need to change therapy defined by one of the following criteria within 5 days: 1) Fresh hematemesis or nasogastric aspiration of ≥100 ml of fresh blood ≥2 h after the start of a specific drug treatment or therapeutic endoscopy; 2) Development of hypovolaemic shock; 3) 3g drop in hemoglobin (9% drop of hematocrit) within any 24 hours period if no transfusion is administered.

    Time frame: 5 days

07

Study locations

19 of 23 sites recruiting
08

References and documents

Publications

  • Bai Z, Li B, Lin S, Liu B, Li Y, Zhu Q, Wu Y, Yang Y, Tang S, Meng F, Chen Y, Yuan S, Shao L, Qi X. Development and Validation of CAGIB Score for Evaluating the Prognosis of Cirrhosis with Acute Gastrointestinal Bleeding: A Retrospective Multicenter Study. Adv Ther. 2019 Nov;36(11):3211-3220. doi: 10.1007/s12325-019-01083-5. Epub 2019 Sep 11. PubMed 31512140 ↗
  • Marcondes MB, Moreno CF, Suzuki CMP, Rodrigues MAG, Moreira A, Qi X, Romeiro FG. Impact of Cirrhosis Etiology and Intensive Care Accessibility on Upper Gastrointestinal Bleeding: A Prospective Observational Study. Can J Gastroenterol Hepatol. 2026;2026(1):e1409025. doi: 10.1155/cjgh/1409025. PubMed 42216795 ↗
  • Zhang S, Sun M, Yuan S, Lin S, Romeiro FG, He Y, Zhu Q, Ma D, Li Y, Philips CA, Liu X, Mendez-Sanchez N, Shao L, Wu Y, Basaranoglu M, Pinyopornpanish K, Chen Y, Mancuso A, Yang L, Tacke F, Li B, Liu L, Ji F, Qi X. Identifying Low-Risk Patients with Cirrhosis and Acute Gastrointestinal Bleeding That May Not Require Urgent Endoscopy. Adv Ther. 2026 Jan;43(1):288-303. doi: 10.1007/s12325-025-03395-1. Epub 2025 Nov 22. PubMed 41273618 ↗
  • Bai Z, Lin S, Sun M, Yuan S, Marcondes MB, Ma D, Zhu Q, Li Y, He Y, Philips CA, Liu X, Pinyopornpanish K, Shao L, Mendez-Sanchez N, Basaranoglu M, Wu Y, Chen Y, Yang L, Mancuso A, Tacke F, Li B, Liu L, Ji F, Qi X. Machine learning based CAGIB score predicts in-hospital mortality of cirrhotic patients with acute gastrointestinal bleeding. NPJ Digit Med. 2025 Jul 31;8(1):489. doi: 10.1038/s41746-025-01883-w. PubMed 40745090 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2025, 47 months after the start.

Of 42 non-industry observational studies under Gastrointestinal Hemorrhage, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 47 months is above that.

Counting every sponsor, half of 47 studies reached it within 36 months; a quarter within 24 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2020
First posted
Dec 10, 2020
StartActual
Jan 1, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04662918
Lead sponsor
Xingshun Qi
Responsible party
Xingshun Qi (Dr., Associate Professor, Vice-Chief Physician, General Hospital of Shenyang Military Region) — Sponsor-investigator
First posted
Dec 10, 2020
Start date
Jan 1, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 7, 2025

Study contacts

Xingshun Qi, Dr.
Contact
xingshunqi@126.com
18909881019
Zhaohui Bai, Dr.
Contact
bai_zhao_hui@foxmail.com
18524451863

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion